Skip to main content

A Phase 2, Open-Label, Single-Arm Study of Pamiparib (BGB-290) for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Homologous Recombination Deficiency (HRD) (Beigene)

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

BeiGene, Ltd

Start Date

January 23, 2020

End Date

September 30, 2020
 

Administered By

Duke Cancer Institute

Awarded By

BeiGene, Ltd

Start Date

January 23, 2020

End Date

September 30, 2020